Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 24:62:386-390.
doi: 10.1016/j.amsu.2021.01.072. eCollection 2021 Feb.

Results of systematic second-look surgery plus hipec in perforated or pt4 colon cancer. Case series

Ángel Serrano Del Moral  1   2 , Estíbalitz Pérez Viejo  1 , Israel Manzanedo Romero  1 , Fernando Pereira Pérez  1   2
Affiliations

Results of systematic second-look surgery plus hipec in perforated or pt4 colon cancer. Case series

Ángel Serrano Del Moral et al. Ann Med Surg (Lond). .

Abstract

Background: Perforated or pT4 colonic tumors have a bad prognosis with a high rate of relapse, including peritoneal relapse (20-30%). Our aim is to analyze the effectiveness of Second Look surgery (SLS) + hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients for early treatment of peritoneal relapse (PR) or for preventing it.

Patients and methods: Patients previously operated for colon cancer, either pT4 or perforated (M0), with no evidence of disease at any level after adjuvant chemotherapy, who undergo systematic SLS + HIPEC (Oxaliplatin 30 min) one year after the initial surgery.

Results: Since February 2014 to July 2018, we performed SLS + HIPEC in 42 patients with M0, either pT4 (n = 33) or perforated (n = 9) colon cancer. Although during SLS there were suspicious lesions in 15 cases (37.5%), they were histologically confirmed in only 4 (9.5%). Histologically confirmed peritoneal relapse (PR) rate at SLS was 6% in pT4 (2/33) and 22.2% in perforated tumors (2/9). Prophylactic HIPEC was performed in all the cases. There was no postoperative mortality. Grade III-IV morbidity occurred in 19% (8/42). With a median follow-up of 33.8 months after primary tumor surgery, 6/42 patients (14.3%) presented peritoneal relapse (PR). 3-year peritoneal disease free survival was 86%, with 3-year disease free survival of 78.6% and 5-year overall survival (OS) of 97.4%.

Conclusion: Peritoneal relapse and survival rates are remarkable in these groups of, a priori, very bad prognosis, which could suggest a beneficial effect of HIPEC.

Keywords: Case series; Colorectal cancer; HIPEC; Peritoneal carcinomatosis; Second look surgery.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest to declare by any of the authors.

References

    1. Mayanagi S., Kashiwabara K., Honda M. Risk factors for peritoneal recurrence in stage II to III colon cancer. Dis. Colon Rectum. 2018;61(7):803–808. doi: 10.1097/DCR.0000000000001002. [doi] - DOI - PMC - PubMed
    1. Koppe M.J., Boerman O.C., Oyen W.J., Bleichrodt R.P. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann. Surg. 2006;243(2):212–222. doi: 10.1097/01.sla.0000197702.46394.16. [doi] - DOI - PMC - PubMed
    1. Segelman J., Granath F., Holm T., Machado M., Mahteme H., Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 2012;99(5):699–705. doi: 10.1002/bjs.8679. [doi] - DOI - PubMed
    1. Jayne D.G., Fook S., Loi C., Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 2002;89(12):1545–1550. [doi] - PubMed
    1. Quere P., Facy O., Manfredi S. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis. Colon Rectum. 2015;58(8):743–752. doi: 10.1097/DCR.0000000000000412. [doi] - DOI - PubMed